Laura Bordone
Director Clinical Development @Ionis Pharmaceuticals, Inc.
Signup · Get unlimited contacts
WORK HISTORY
Director Clinical Development @Ionis Pharmaceuticals, Inc.
Carlsbad, CA, US
Global Program Team Leader for donidalorsen (Dawnzera), an RNA-based therapeutic for hereditary angioedema (HAE):• Directed the global development strategy from early clinical phases through late-stage trials, achieving FDA approval on August 21, 2025• Provide strategic oversight of global clinical programs, including study design, execution, and data evaluation to ensure safety, efficacy, and regulatory readiness• Lead cross-functional collaboration across clinical operations, regulatory affairs, medical affairs, and commercial teams, serving as a key supporting partner for clinical and regulatory functions• Partner with investigators, CROs, and vendors to deliver high-quality clinical data and operational outcomes• Guide and support global regulatory submissions (NDA, CSRs, IB, PIP, ODD) and scientific communications, including publications, abstracts, and conference presentations• Core member of IonisNEXT ERG, engaging students in STEM education and mentoring future leaders in science
EDUCATION
Massachusetts Institute of Technology
Postdoctoral fellow
University of Minnesota
PhD, Pharmacology
Università degli Studi di Milano
Laurea, Biology
BIOCOM Institute
BioCollaborative Life Science Immersion Program, BRIDGE Grant
SKILLS
ABOUT LAURA BORDONE
Pharmaceutical leader with proven expertise in clinical drug development and global program leadership. Successfully led donidalorsen (Dawnzera) from Phase 2 through FDA approval and currently serve as Global Program Team Leader, driving strategy and execution in late-stage development for hereditary angioedema (HAE).
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.